Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products. The Company is very pleased to report the continuing successful progress by patient who has been topically self-administering Cannabis Science extracts for Squamous Cell Carcinoma Cancer. Cannabis Science is in a unique position to evaluate the effectiveness of different formulations by working closely with physicians and patients in medical marijuana states where patients can determine the effectiveness of various cannabis-based formulations.

For example, as previously announced, this patient has photo-documented dramatic shrinkage and subsequent disappearance in the cancer tumor. We will release documentation to the public once treatment is completed and has been properly confirmed by clinical biopsy.

Cannabis Science is focused on establishing clinically confirmed data that will lead to standardized products under the Cannabis Science label, thus confirming the numerous anecdotal reports confirming the anti-cancer properties of whole cannabis and cannabinoid extracts.

Cannabis Science is committed to making cannabis-based medicines available to the public as rapidly as possible. The Company is taking multiple approaches to accomplishing this aim in the United States. The science of cannabinoids has exploded over the past decade, laying the scientific foundation for the many medicinal uses of this unique plant. Cannabinoids are a class of biologically active compounds produced by all vertebrates (endocannabinoids) the Cannabis plant (phytocannabinoids), and more recently patentable synthetic compounds produced by chemists. Today's modern peer-reviewed science supports the many historical uses that were discovered over thousands of years of medicinal use by herbalists.

Cannabis Science, in conjunction with several Colorado-licensed dispensaries and physicians, consults with a number of cancer patients who were seeking to inform themselves of the current peer-reviewed scientific literature, regarding modern and historical use of cannabis preparations for treating cancers so that they can make informed decisions regarding their self-directed, self administered cancer treatment.

The first two Cannabis Science Brand Formulations, Cannabis Science CT-1 and Cannabis Science MT-1 are now available at both Cannabis Therapeutics and Marisol Therapeutics exclusively for Colorado State licensed medical marijuana patients.

Cannabis Science MT-1: Produced by Marisol Therapeutics: A family-owned shop, Marisol Therapeutics was founded to assist medical marijuana patients in obtaining medical marijuana in Colorado. They believe patients have the right to safe, confidential, quality medical marijuana and products. They recommend medical marijuana from their own experience with unrelenting and previously untreatable pain. "We understand, we care, we want you to heal." Marisal Therapeutics has produced a custom blend of but is derived from their proprietary strains that were developed over 30 years by a Native American Vietnam veteran in order to address his medical needs. Cannabis Science CT-1 has been analyzed and shown to be free of insecticides and molds. The product is produced in soil under organic roof conditions.

ADDRESS: 922 Kimble Drive, Pueblo West, CO 81007

PHONE: 719-547-4000

EMAIL: info@marisolmed.com or http://marisolmed.com/ for more information.

Cannabis Science CT-1: Produced by Cannabis Therapeutics was Colorado's first dispensary. Working with local law enforcement, state officials, legal experts, medical physicians, and researchers, Cannabis Therapeutics sets a standard of both safety and consistent quality to its members as well as the community at large. Cannabis Therapeutics is a professional medical business that employs all its policies and regulations to ensure the most stringent adherence to the law. Second in importance to legality is implementation of standardizing techniques to ensure both repeatability in dosing and quality of medicine. Cannabis Therapeutics began as an organization built by individuals that did not receive satisfactory relief from conventional therapies. Cannabis Therapeutics has produced a high quality cannabis extract from a custom blend of buds hydroponically grown medical marijuana strains. Cannabis Science CT-1 has been analyzed and shown to be free of insecticides and molds.

ADDRESS: 907 E Fillmore St., Colorado Springs, CO 80907

http://www.cannabistherapeutics.net/ for more information.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science Inc.
Dr. Robert J. MelamedePresident & CEO1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane
Investor Relations Management
1-561-234-6929
info@cannabisscience.com
www.cannabisscience.com